Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse(TM)
March 25, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 25, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved...
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
March 19, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 19, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective...
Catalyst Pharmaceutical Partners to Present at the 26th Annual ROTH Conference
March 06, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 6, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 26th Annual ROTH Conference, in...
Catalyst Pharmaceutical Partners Observes Rare Disease Day Today
February 28, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved...
Catalyst Pharmaceutical Partners to Present at 16th Annual BIO CEO & Investor Conference
February 06, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), today announced that the Company will be presenting at the 16th Annual BIO CEO & Investor...
Catalyst Pharmaceutical Partners Reports Positive Cardiac Safety Results of Its Phase 3 Product, Firdapse Tablets
January 08, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved...
Catalyst Pharmaceutical Partners Reports Dismissal of Stockholder Class Action Lawsuit
January 07, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective,...
Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program
January 06, 2014 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
First Meeting With FDA Since Receiving Breakthrough Therapy Designation for Firdapse
Anticipated Timeline for NDA Submission Remains on Track
CORAL GABLES, Fla., Jan. 6, 2014 (GLOBE NEWSWIRE) --...
Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia
November 18, 2013 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved...
Catalyst Pharmaceutical Partners Announces Third Quarter 2013 Financial Results
November 14, 2013 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved...